Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)
- 1 December 1982
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 18 (12), 1285-1292
- https://doi.org/10.1016/0277-5379(82)90130-4
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide systemJournal of Medicinal Chemistry, 1981
- Symbols in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1980
- METABOLISM AND DISPOSITION STUDIES OF 9-HYDROXYELLIPTICINE AND 2-METHYL-9-HYDROXYELLIPTICINIUM ACETATE IN ANIMALS1980
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979
- High-performance liquid chromatographic separation and trace determination of the antitumour derivatives of ellipticine and related quaternary ammonium compoundsJournal of Chromatography A, 1979
- 55 Peroxidases-catalyzed oxidation of the antitumor drug 9-hydroxy-ellipticineBiochimie, 1978
- Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264-137) in advanced human cancersEuropean Journal of Cancer (1965), 1978
- Synthese de l'hydroxy-9 ellipticine (14C-1) ou hydroxy-9 dimethyl-5, 11 (6h) pyrido [4,3-b] carbazole (14C-1)Journal of Labelled Compounds and Radiopharmaceuticals, 1975
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974
- Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage scheduleCancer, 1974